New Age Alpha Advisors LLC Takes Position in Organon & Co. (NYSE:OGN)

New Age Alpha Advisors LLC acquired a new position in Organon & Co. (NYSE:OGN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 50,517 shares of the company’s stock, valued at approximately $754,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. raised its holdings in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Weiss Asset Management LP purchased a new stake in Organon & Co. in the third quarter valued at approximately $32,966,000. Norges Bank purchased a new stake in Organon & Co. in the fourth quarter valued at approximately $25,258,000. Magnetar Financial LLC lifted its position in Organon & Co. by 560.2% during the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company’s stock valued at $25,878,000 after purchasing an additional 1,471,731 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in Organon & Co. by 303.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after buying an additional 934,505 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $14.92 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock has a market cap of $3.85 billion, a PE ratio of 4.48, a PEG ratio of 0.90 and a beta of 0.76. The company’s fifty day moving average is $15.32 and its 200 day moving average is $16.17. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.51%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s dividend payout ratio is 33.63%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays lowered their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Organon & Co. presently has an average rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.